Literature DB >> 27243381

Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.

Jordan M Cloyd1, Christopher H Crane2, Eugene J Koay2, Prajnan Das2, Sunil Krishnan2, Laura Prakash1, Rebecca A Snyder1, Gauri R Varadhachary3, Robert A Wolff3, Milind Javle3, Rachna T Shroff3, David Fogelman3, Michael Overman3, Huamin Wang4, Anirban Maitra4, Jeffrey E Lee1, Jason B Fleming1, Matthew H G Katz1.   

Abstract

BACKGROUND: Previous studies have suggested that preoperative chemoradiation (CRT) is associated with an improved margin-negative resection rate among patients who undergo pancreatoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC). However, the optimal preoperative regimen has not been established.
METHODS: All patients with PDAC who received chemotherapy and/or CRT followed by PD between 1999 and 2014 were retrospectively reviewed. The effects of 2 external-beam radiation regimens-a standard course of 50.4 Gy in 28 fractions and a hypofractionated course of 30 Gy in 10 fractions-were compared. Differences in clinicopathologic characteristics, locoregional recurrence (LR), and overall survival (OS) were assessed.
RESULTS: Among 472 patients who received preoperative therapy, 224 (47.5%) received 30 Gy, 221 (46.8%) received 50.4 Gy, and 27 (5.7%) received chemotherapy alone. Patients who received 50.4 Gy were more likely to have advanced-stage disease and to have received induction and postoperative chemotherapy, but there was no difference in the R1 margin status, treatment effect, LR, or OS between the 2 radiation groups (all P values > .05). Patients who received preoperative CRT had a lower rate of LR than patients who received preoperative chemotherapy alone (P < .01). In a multivariate Cox proportional hazards analysis, 50.4 Gy was associated with OS and LR similar to those associated with 30 Gy, whereas the absence of preoperative radiation was associated with a higher rate of LR (odds ratio, 2.21; 95% confidence interval, 1.04-4.70) and similar OS.
CONCLUSIONS: Preoperative hypofractionated CRT was associated with similar local control and OS in comparison with standard CRT in patients undergoing PD for PDAC. The use of chemotherapy alone without CRT was associated with poorer local control but similar survival. Cancer 2016.
© 2016 American Cancer Society. Cancer 2016;122:2671-2679. © 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  FOLFIRINOX; chemoradiation; chemotherapy; gemcitabine; local recurrence; neoadjuvant therapy; pancreatectomy; pancreatic cancer; whipple

Mesh:

Year:  2016        PMID: 27243381      PMCID: PMC4992463          DOI: 10.1002/cncr.30117

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

1.  Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results.

Authors:  Matthew H G Katz; Syed A Ahmad; Judy C Boughey
Journal:  Bull Am Coll Surg       Date:  2015-10

2.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

Review 3.  Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?

Authors:  Michael D Chuong; Drexell H Boggs; Kruti N Patel; William F Regine
Journal:  J Gastrointest Oncol       Date:  2014-06

4.  A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma.

Authors:  Theodore P McDade; Joshua S Hill; Jessica P Simons; Bilal Piperdi; Sing Chau Ng; Zheng Zhou; Sidney P Kadish; Thomas J Fitzgerald; Jennifer F Tseng
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

5.  Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.

Authors:  Jordan Kharofa; Susan Tsai; Tracy Kelly; Clint Wood; Ben George; Paul Ritch; Lauren Wiebe; Kathleen Christians; Douglas B Evans; Beth Erickson
Journal:  Radiother Oncol       Date:  2014-10-15       Impact factor: 6.280

6.  Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.

Authors:  Deyali Chatterjee; Matthew H Katz; Asif Rashid; Gauri R Varadhachary; Robert A Wolff; Hua Wang; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Christopher Crane; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Cancer       Date:  2011-10-25       Impact factor: 6.860

7.  Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma.

Authors:  Jennifer L Gnerlich; Samuel R Luka; Anjali D Deshpande; Bernard J Dubray; Joshua S Weir; Danielle H Carpenter; Elizabeth M Brunt; Steven M Strasberg; William G Hawkins; David C Linehan
Journal:  Arch Surg       Date:  2012-08

8.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

Authors:  Douglas B Evans; Gauri R Varadhachary; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Huamin Wang; Karen R Cleary; Gregg A Staerkel; Chusilp Charnsangavej; Elizabeth A Lano; Linus Ho; Renato Lenzi; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

9.  Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer.

Authors:  Rosa F Hwang; Huamin Wang; Axbal Lara; Henry Gomez; Tracy Chang; Nicole Sieffert; Younghee Moon; Sabina Ram; Stuart Zimmerman; Jeffrey H Lee; Peter W T Pisters; Eric P Tamm; Jason B Fleming; James L Abbruzzese; Douglas B Evans
Journal:  Ann Surg Oncol       Date:  2008-02-07       Impact factor: 5.344

10.  Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.

Authors:  Henriette Golcher; Thomas B Brunner; Helmut Witzigmann; Lukas Marti; Wolf-Otto Bechstein; Christiane Bruns; Henry Jungnickel; Stefan Schreiber; Gerhard G Grabenbauer; Thomas Meyer; Susanne Merkel; Rainer Fietkau; Werner Hohenberger
Journal:  Strahlenther Onkol       Date:  2014-09-25       Impact factor: 3.621

View more
  14 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality.

Authors:  Jason W Denbo; Morgan L Bruno; Jordan M Cloyd; Laura Prakash; Jeffrey E Lee; Michael Kim; Christopher H Crane; Eugene J Koay; Sunil Krishnan; Prajnan Das; Bruce D Minsky; Gauri Varadhachary; Rachna Shroff; Robert Wolff; Milind Javle; Michael J Overman; David Fogelman; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2016-10-11       Impact factor: 3.452

3.  Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy.

Authors:  Jordan M Cloyd; Graciela M Nogueras-González; Laura R Prakash; Maria Q B Petzel; Nathan H Parker; An T Ngo-Huang; David Fogelman; Jason W Denbo; Naveen Garg; Michael P Kim; Jeffrey E Lee; Ching-Wei D Tzeng; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2017-12-11       Impact factor: 3.452

4.  Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.

Authors:  Jordan M Cloyd; Matthew H G Katz; Laura Prakash; Gauri R Varadhachary; Robert A Wolff; Rachna T Shroff; Milind Javle; David Fogelman; Michael Overman; Christopher H Crane; Eugene J Koay; Prajnan Das; Sunil Krishnan; Bruce D Minsky; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William Ross; Priya Bhosale; Eric P Tamm; Huamin Wang; Anirban Maitra; Michael P Kim; Thomas A Aloia; Jean-Nicholas Vauthey; Jason B Fleming; James L Abbruzzese; Peter W T Pisters; Douglas B Evans; Jeffrey E Lee
Journal:  J Gastrointest Surg       Date:  2016-10-24       Impact factor: 3.452

5.  Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.

Authors:  Jordan M Cloyd; Huamin Wang; Michael E Egger; Ching-Wei D Tzeng; Laura R Prakash; Anirban Maitra; Gauri R Varadhachary; Rachna Shroff; Milind Javle; David Fogelman; Robert A Wolff; Michael J Overman; Eugene J Koay; Prajnan Das; Joseph M Herman; Michael P Kim; Jean-Nicolas Vauthey; Thomas A Aloia; Jason B Fleming; Jeffrey E Lee; Matthew H G Katz
Journal:  JAMA Surg       Date:  2017-11-01       Impact factor: 14.766

6.  Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma.

Authors:  Suguru Yamashita; Michael J Overman; Huamin Wang; Jun Zhao; Masayuki Okuno; Claire Goumard; Ching-Wei Tzeng; Michael Kim; Jason B Fleming; Jean-Nicolas Vauthey; Matthew H Katz; Jeffrey E Lee; Claudius Conrad
Journal:  Ann Surg Oncol       Date:  2017-10-04       Impact factor: 5.344

7.  Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy.

Authors:  Douglas S Swords; Samual R Francis; Shane Lloyd; Ignacio Garrido-Laguna; Sean J Mulvihill; Joshua D Gruhl; Miles C Christensen; Gregory J Stoddard; Matthew A Firpo; Courtney L Scaife
Journal:  J Gastrointest Surg       Date:  2018-09-05       Impact factor: 3.452

8.  Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Jordan M Cloyd; Victor Heh; Timothy M Pawlik; Aslam Ejaz; Mary Dillhoff; Allan Tsung; Terence Williams; Laith Abushahin; John F P Bridges; Heena Santry
Journal:  J Clin Med       Date:  2020-04-15       Impact factor: 4.241

9.  Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.

Authors:  Dongguang Wei; Mohamed M Zaid; Matthew H Katz; Laura R Prakash; Michael Kim; Ching-Wei D Tzeng; Jeffrey E Lee; Anshuman Agrawal; Asif Rashid; Hua Wang; Gauri Varadhachary; Robert A Wolff; Eric P Tamm; Priya R Bhosale; Anirban Maitra; Eugene J Koay; Huamin Wang
Journal:  Pancreatology       Date:  2020-11-14       Impact factor: 3.996

10.  Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.

Authors:  Adam R Wolfe; Dhivya Prabhakar; Vedat O Yildiz; Jordan M Cloyd; Mary Dillhoff; Laith Abushahin; Dayssy Alexandra Diaz; Eric D Miller; Wei Chen; Wendy L Frankel; Anne Noonan; Terence M Williams
Journal:  Cancer Med       Date:  2020-05-16       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.